OECD WORKSHOP 2000 ON HEALTHY AGEING AND BIOTECHNOLOGY RESEARCH AND POLICY ISSUES

Size: px

Start display at page:

Download "OECD WORKSHOP 2000 ON HEALTHY AGEING AND BIOTECHNOLOGY RESEARCH AND POLICY ISSUES"

Randall Cobb
6 years ago
Views:

1 OECD WORKSHOP 2000 ON HEALTHY AGEING AND BIOTECHNOLOGY RESEARCH AND POLICY ISSUES To be held in Tokyo, Japan, on November 13-14, 2000 DRAFT PROGRAMME

2 Date: 13 November - 14 November 2000 Location: Attendance: National Institute of Health Service Management Toyama-cho, Shinjuku-ku, Tokyo. Tel: By invitation only, limited to approximately 120 participants from around the world, including experts from academia, industry, international organisations, and OECD government representatives. Purpose: The OECD Tokyo Workshop on Healthy Ageing and Biotechnology will identify the scientific and health care policy issues that are emerging for OECD countries as biotechnologies extend our understanding of the ageing process. Biotechnology may offer new ways to detect, prevent, or treat age-related diseases and conditions, reducing both the level of disability and the costs associated with care for the elderly. Speakers will discuss what age-related diseases and conditions are most prevalent and most costly and what major scientific advances hold the promise of improving elderly health. Workshop participants will also discuss the health and social policy choices facing OECD countries as they consider new treatments and technologies. In the long run such new treatments may be very important in decreasing disabilities or enhancing the participation of the elderly in society, but in the short run they face important roadblocks to their development, diffusion, and use. Participants will consider policies that will promote healthy ageing in OECD countries to benefit the elderly, their families and society as a whole. Such mutual exchange of knowledge and experience among OECD Member countries in the area of health care technology may help member countries to develop policy guidelines to promote efficient and cost-effective ways of decreasing disabilities and enhancing the ways the elderly participate in society. The Workshop is being held under the auspices of the OECD Working Party on Biotechnology and is primarily funded through a grant by Japan. Workshop Chairman: Workshop Objectives: Keynote Speaker: Chair Session 1: Chair Session 2: Chairs Session 3: Chairs Session 4: N. SAKAI, Director General for Science and Technology, MHW, Japan R. NEZU, Director, Directorate for Science, Technology and Industry, OECD R. FOGEL, University of Chicago, US SOCIO-ECONOMIC SCENE SETTING S.WALD, OECD THE SCIENTIFIC SCENE FOR AGEING AND BIOTECHNOLOGY H.YOSHIKURA, International Medical Centre, Japan CASE STUDIES OF HOW BIOTECHNOLOGY MAY HELP ALLEVIATE THE BURDEN OF DISEASE A. POMPIDOU, Hôpital Cochin, France S. KARJALAINEN, Research Council for Health, Finland L. MIDDLETON, Glaxo Wellcome, UK INTERNATIONAL FORUM AND POLICY CONSIDERATIONS D. PERRY, Alliance for Aging Research, US A. SEITER, Novartis, Switzerland H. YOSHIKURA, International Medical Centre, Japan M.WEKSLER, Cornell University Medical College, US Rapporteurs: Overall Rapporteur: M.WEKSLER, Cornell University Medical College, US Scientific Issues: E. RONCHI, OECD Policy Issues: B. CALLAN, OECD 2

3 DAY 1 MONDAY, 13 NOVEMBER REGISTRATION WELCOMING ADDRESS AND WORKSHOP GOALS/OBJECTIVES Workshop Chairman: Workshop Objectives: Keynote Speaker: N. SAKAI, Director General for Science and Technology, Ministry of Health and Welfare, Japan R. NEZU, Director of DSTI, OECD R. FOGEL, University of Chicago, US SESSION 1: THE SOCIO-ECONOMIC SCENE SETTING S. WALD, OECD Coffee 1.1. Demographic and Epidemiological Trends The costs of Elderly Health Care in the OECD Speaker: S. JACOBZONE, OECD 1.2. Burden of Disease and Disability-Adjusted Life Years in Priority Setting A Focus on Health Problems at Older Age Speaker: T. VOS, Department of Human Services, Australia How Countries Can Meet the Challenge of Ensuring Active Ageing and Quality of Life Improvements Speaker: V. TAIPALE, STAKES, Finland Discussant: E. BUSER, Novartis, Switzerland Lunch SESSION 2: THE SCIENTIFIC SCENE FOR AGEING AND BIOTECHNOLOGY H. YOSHIKURA, International Medical Centre, Japan Coffee 2.1. The Biology of Ageing New Theories in Molecular and Cellular Biology Speaker: C. HARLEY, Geron Corporation, US 2.2. Genetics, Genomics and Ageing Diagnostics, Therapeutics and Clinical Use Speaker: D. SCHLESSINGER, National Institute on Aging, US Discussant: L. MIDDLETON, Glaxo-Wellcome, UK - Pharmacogenetics and Age-Related Diseases, 3

4 SESSION 3: CASE STUDIES OF HOW BIOTECHNOLOGY MAY HELP ALLEVIATE THE BURDEN OF DISEASE A: Progressive Cognitive Impairment Alzheimer s and Parkinson s Disease A. POMPIDOU, Hôpital Cochin, France 3.1. Epidemiology and Economics Speaker: A. HOFMAN, Erasmus Medical Centre, Netherlands 3.2. Diagnosis, Immunisation, Gene & Cell Therapies for Alzheimer s Disease Speaker: L. THAL, University of California San Diego, US 3.3. Neurodegeneration in Parkinson s Disease Speaker: B. SOMMER, Novartis, Switzerland B: Mobility/Frailty Osteoporosis, Osteoarthritis, Muscle Frailty, Instability S. KARJALAINEN, Research Council for Health, Finland 3.4. Epidemiology and Economics Speaker: S. MAGGI, National Research Council, Italy 3.5. Hormone Replacement, Bio-Regeneration Speaker: D. MACLEAN, Pfizer Global Research and Development, US 3.6. Biomaterials, Artificial Joints Speaker: R. HUISKES, University of Nijmegen, Netherlands EVENING RECEPTION AND DINNER WILL BE OFFERED BY THE HOST COUNTRY 4

5 DAY 2 TUESDAY, 14 NOVEMBER SESSION 3: CASE STUDIES OF HOW BIOTECHNOLOGY MAY HELP ALLEVIATE THE BURDEN OF DISEASE (continued) L. MIDDLETON, Glaxo Wellcome, UK C: Common Complex Disorders Vascular Disease and Cancer 3.7. Use and Misuse of Pharmaceuticals in the Elderly with Cardiovascular Disease Speaker: N. FREEMANTLE, University of York, UK 3.8. Vascular Disease Gene Therapies Speaker: A. BAKER, University of Glasgow, UK 3.9. International Epidemiological Perspectives in Cancer Speaker: F. BERRINO, Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy Cancer Gene Therapies and Other Novel Technologies Speaker: M. SADELAIN, Memorial Sloan Kettering, US Discussant: S. JACOBZONE, OECD, - Perspectives from the OECD Ageing-Related Diseases Study (ischemic heart disease and breast cancer) Coffee SESSION 4: INTERNATIONAL FORUM AND POLICY CONSIDERATIONS A: Roadblocks to the Development, Dissemination and Use of New Technologies for Older Persons D. PERRY, Alliance for Aging Research, US 4.1. Speeding Access to Important New Drugs: The Challenge of Developing New Pharmaceutical Products for the Elderly Speaker: K. KAITIN, Tufts University, US 4.2. Government Science and Health Policy Strategies Speaker: M. TERADA, National Cancer Centre, Japan 4.3. Dissemination of New Biotechnologies Through Telemedicine Speaker: A. POMPIDOU, Hôpital Cochin, France 4.4. Barriers to the Implementation of Advanced Technologies in Clinical Practice and Care for the Elderly Speaker: E. TOPINKOVÁ, Charles University, Czech Republic 5

6 Lunch Demonstration: by Dr. Yvonne HASLER, Novartis Foundation for Gerontology, Switzerland B: Access to New Technologies Approaches to Equity, Rationing and Empowerment A. SEITER, Novartis, Switzerland 4.6. Long-term care for Older People: Reconciling Budgetary Constraint and Quality Improvement Speaker: A.WALKER, University of Sheffield, UK 4.7. New Policies for Long Term Care of the Elderly Disabled in Japan Speaker: M. NISHIYAMA, Ministry of Health and Welfare, Japan 4.8. Long Term Care Insurance in Germany Speaker: R. VOLLMER, Ministry of Health, Germany 4.9. Disabilities and Access to Care of the Elderly in Iceland Speaker: P. JÓNSSON, University of Iceland, Iceland Strategies for Avoiding Elderly Exclusion and Mistreatment Speaker: Lady GREENGROSS, Director General, The National Council on Ageing, UK Coffee C: International Issues - Information Gaps and Opportunities for Co-operation Co-chairs: Panellists: H.YOSHIKURA, International Medical Centre, Japan M.WEKSLER, Cornell University Medical College, US S. WALD, OECD A. MAEDA, World Bank, US G. MEZELAS, European Commission, Belgium R. SUZMAN, National Institute on Aging, US P. SCHERER, OECD SESSION 5: SUMMARY AND CLOSING REMARKS 5.1. Summary of Main Points M. WEKSLER, Cornell University Medical College, US 5.2. Possible Outcomes for the Working Party on Biotechnology E. RONCHI, OECD 5.3. Closing Remarks N. SAKAI, Ministry of Health and Welfare, Japan 6

7 7

The EFGCP Children s Medicines Working Party 3 rd Annual Conference EU Paediatric Regulation: First European Experiences & Strategic Outlook

The EFGCP Children s Medicines Working Party 3 rd Annual Conference EU Paediatric Regulation: First European Experiences & Strategic Outlook 9 October 2007 - Management Centre Europe, Brussels, Belgium